Genetic Fusion Detection May Benefit NSCLC Patients
A case study from the University of Colorado suggests that traditional gene testing for NSCLC patients may not be sufficient for detecting potential oncogenic drivers.
Woman With a Polypoid Endometrial Tumor
A 52-year-old woman presents with a polypoid endometrial tumor. What is your diagnosis?
Daratumumab May Benefit Myeloma Patients Ineligible for ASCT
The phase III ALCYONE study showed that daratumumab in combination with bortezomib, melphalan, and prednisone is a viable front-line option for myeloma patients who are not candidates for ASCT.
Liquid Biopsies Could Help Guide Therapy in Carcinoma of Unknown Primary
A recent study suggests that next-generation sequencing of circulating tumor DNA is feasible in carcinoma of unknown primary, which could facilitate targeted therapy for this hard-to-treat disease.
CTCs May Help Guide Therapy and Predict Poor Prognosis in Lung Cancer Patients
Circulating tumor cells isolated from early stages of lung cancer may be predictive of poor prognosis and could potentially be predictive biomarkers of disease recurrence.
Triple Drug Approach May Halt Acute Lymphoblastic Leukemia
Researchers have discovered a three-drug combo that may combat acute lymphoblastic leukemia by shutting down the production of nucleotides that activate a DNA replication stress response.
Dozens of New Genes Associated With Cancer Treatment Resistance Are Identified
Using a CRISPR gene editing technique, researchers have identified dozens of new genes that create T-cell resistant cancer.
Combating MYCN-Driven Leukemogenesis May Benefit AML Patients
Researchers at St. Jude Children’s Research Hospital have discovered a vulnerability that may easily translate into new targeted drug therapies that block heme biosynthesis, killing leukemic cells.
Man With Mass in Upper Arm
A 39-year-old man presents with a mass in the right upper arm. What is your diagnosis?
Precision Medicine Could Soon Be a Reality for Gastric Cancer
A new study has shown that it may now be possible to predict survival outcomes and patients’ response to chemotherapy based on the molecular classification of four distinct subtypes of gastric cancer.
By clicking Accept, you agree to become a member of the UBM Medica Community.